Mascotte to Buy Controlling 50.1% Stake of Taiwan-Based Sun Materials

Mascotte Holdings Limited ("Mascotte" or the "Company"; stock code 136.HK) is pleased to announce that it will acquire a controlling 50.1% stake of Sun Materials, a Taiwan-based polycrystalline silicon manufacturer, with a consideration of US$150,000,000 (approximately HK$1,170,000,000).

The Company has reserved the right to acquire the remaining 49.9% share stake, based on the agreement.

Mascotte has established a strategic alliance with Hareon under a strategic cooperation agreement. Headquartered in Jiangsu, China, Hareon is a rapidly growing, vertically integrated manufacturer of solar photovoltaic products including ingot, block, wafers, cells and modules with a global customer base. In addition, Hareon agreed to purchase polycrystalline silicon from Sun Materials after the production plant commences operations. The polycrystalline silicon quality of Sun Materials has been tested by Hareon after carrying out two polycrystalline silicon production trials in December 2010 and January 2011. On the basis of Hareon's indication of the testing results, Mascotte is pleased to accept that the trial results have fulfilled the relevant conditions for the transaction.

Sun Materials is a Taiwan-based polycrystalline silicon manufacturer and it has developed a new and innovative industry changing technology for solar grade polycrystalline silicon which has obtained patents in the US, Europe, Japan, Taiwan and China. Its technology will help to produce high quality solar grade polycrystalline silicon used in the solar energy value chain with a view to significantly reduce the plant construction costs, production costs, production hazards and adverse environmental effects of manufacturing solar grade polycrystalline silicon. Mascotte believes that Sun Materials' production process is a "disruptive innovation" that has the potential to radically transform the industry landscape in the clean technology market and the transaction will give Mascotte the opportunity to benefit from technology, with the potential to capture a leading position in the solar grade polysilicon market.

Polycrystalline silicon is a primary raw material used in the solar energy value chain. The traditional "Siemens" process of manufacturing polycrystalline silicon is being associated with environmental risks and general safety concerns by the industry. Compared to the traditional and modified "Siemens" processes and the FBR process, which are commonly used by manufacturers of solar grade polysilicon, Sun Materials considers the production process it intends to adopt to be innovative in that it uses modular production lines and is designed with a view to using lower cost feedstock while substantially reducing the consumption of electricity and water. Sun Materials believes that its technology will significantly assist in reducing the production cost and the adverse environmental effects of manufacturing polycrystalline silicon. This potentially translates into a lower cost of polycrystalline silicon procurement by downstream customers in the solar energy value chain which may allow them to deliver a product that can generate electricity at or below grid parity without the aid of subsidies. Based on the foregoing, the Directors believe that Sun Materials could potentially enjoy the best profit margins in the industry after achieving economies of scale, and at the same time maintain its cost-competitiveness. Its target customers are downstream manufacturers of wafers, ingots and photovoltaic cells. The production will commence in the first quarter of 2011.

Sun Materials has already secured contracts with purchasers of its polycrystalline silicon for all of its production output for 2011. Sun Materials also secured its sales contracts with other domestic and international customers with the latest contract period extending to 2021.

Sun Materials' plant in Taiwan is designed for a production capacity of up to 3,500 metric tons. Mascotte also plans to expand its production line this year and build another 5 plants to increase its production capacity up to 21,000 metric tons by the first quarter of next year in order to fulfill the large orders and demand from customers.

In the meantime, Mascotte entered into a subscription agreement with Mr. Samuel Yang and Improve Forever on 12 January 2011 to issue an aggregate of 354,100,608 shares with a price of HK$0.4 per share, amounting to approximately HK$141,000,000. Mr. Yang demonstrates his long-term commitment to Mascotte by agreeing to a minimum commitment of at least 2 years. Mr. Samuel Yang is the vice-chairman and chief executive officer of Hareon. He is the founder of NASDAQ-listed JA Solar Holdings Co., Ltd. (NASDAQ: JASO) and a co-founder of Suntech Power Holdings Co., Ltd. (NYSE: STP) and China Sunergy Holdings Co., Ltd. (NASDAQ: CSUN).

In order to complete the acquisition, Mascotte proposes to place the placing shares and the convertible bonds with a view to raising an aggregate amount of approximately HK$2.8 billion to fund the acquisition, the expansion plan and the capital expenditure for Sun Materials. Deutsche Bank is the financial adviser and placing agent for Mascotte.

Commenting on the transaction, the chairman of Mascotte, Mr. Peter Whitelam expressed "It's a significant milestone for Mascotte. Upon the completion, we will engage in the polycrystalline silicon manufacturing business, which has high growth potential as clean energy is an important topic across the world. We are glad to be part of it. Also, our technology is very competitive and low cost which will drive massive demand in the long run. We can foresee that the business will grow rapidly and bring significant contribution to our revenue soon."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.